Systemic sclerosis & Raynaud's
Bicaudal D2 autoantibodies are highly specific for systemic sclerosis
Authors' conclusion
Autoantibodies against BICD2 were highly specific for SSc patients.
Study context
- Population
- Patients with connective tissue disease and healthy controls (blood donors)363 patients with CTD
- Participants
- 121 / 141 / 101 / 100
- Exposure
- Anti-BICD2 in systemic sclerosis (SSc) vs other connective tissue diseases and blood donors
- SScn = 121
- SLEn = 141
- Myositisn = 101
- Blood donorsn = 100reference
- Outcome
- Prevalence of anti-BICD2
Main finding
As reported in the abstract
Anti-BICD2 in SSc
| Group | Value | Specificity | Sensitivity |
|---|---|---|---|
| SSc | 35 events | 96.5% | 28.9% |
SSc
Value35 events
Specificity96.5%
Sensitivity28.9%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Lung function, anti-BICD2-positive vs anti-BICD2-negative SScAnti-BICD2-positive vs Anti-BICD2-negative | P = 0.01 |
| Lung function, anti-BICD2-positive vs anti-BICD2-negative SScAnti-BICD2-positive vs Anti-BICD2-negative | P = 0.01 |
| Lung function, anti-BICD2-positive vs anti-BICD2-negative SScAnti-BICD2-positive vs Anti-BICD2-negative | P = 0.03 |
Co-occurrence with centromere autoantibodies in anti-BICD2-positive SSc
- Anti-BICD2 and centromere autoantibodies present together
- 91%
- Anti-BICD2 the only antibody present
- 0
Original publication
Bicaudal D2 autoantibodies are highly specific for systemic sclerosis. Scand J Rheumatol. Published 24 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →